CMMB — Chemomab Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Chemomab Therapeutics To Discuss Fourth Quarter Results
Chemomab Therapeutics Ltd expected to post a loss of 4 cents a share - Earnings Preview
Chemomab Therapeutics Ltd expected to post a loss of 4 cents a share - Earnings Preview
Chemomab Therapeutics Ltd expected to post a loss of 4 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-VerifyMe, Molson Coors, Sigma Lithium
U.S. STOCKS ON THE MOVE-Chemomab, Home Depot, Teck Resources
Chemomab jumps on FDA nod for mid-stage trial of rare skin disease drug
Brief: Chemomab Announces FDA Clearance Of Investigational New Drug Application For Phase 2 Clinical Trial Of Cm-101 In Patients With Systemic Sclerosis
Brief: Chemomab Therapeutics Files For ADS Offering Size Not Disclosed
Refile: BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Starbucks, ASLAN Pharma
U.S. STOCKS ON THE MOVE-Jasper Therapeutics, Blackstone, Mondelez
Chemomab Therapeutics up as liver fibrosis drug meets mid-stage study goals
U.S. STOCKS ON THE MOVE-Horizon Global, Apple, PayPal Holdings
Brief: Chemomab Reports Top-Line Results From Cm-101 Phase 2A Liver Fibrosis Biomarker Trial In Nash Patients
Chemomab Therapeutics jumps as liver fibrosis drug meets goals in mid-stage study
Brief: Chemomab Reports Independent Drug Monitoring Committee Safety Review Of CM-101 Phase 2 Trial
Brief: Chemomab Appoints Mitchell Jones As Vice President Of Corporate Development & Strategy
Founders
Brief: Chemomab Announces Appointment Of Matthew Frankel As Chief Medical Officer